Table 1.
Clinical and biochemical characteristics of control and HFrEF groups
| Variables | Control (n = 176) | HFrEF (n = 168) | P |
|---|---|---|---|
| Age (years) | 55.11 ± 13.44 | 57.25 ± 14.92 | 0.418 |
| Sex, male (%) | 116 (65.9%) | 122(72.6%) | 0.199 |
| BMI (Kg/m2) | 21.72 ± 1.78 | 23.45 ± 3.80 | < 0.001 |
| Diabetes mellitus (%) | 0(0%)a | 40 (23.8%) | < 0.001 |
| Hypertension (%) | 0(0%)a | 66 (39.3%) | < 0.001 |
| Myocardial infarction (%) | 0(0%)a | 52 (31.0%) | < 0.001 |
| Systolic pressure (mmHg) | 108.86 ± 15.70 | 119.04 ± 20.71 | 0.071 |
| Diastolic pressure (mmHg) | 71.41 ± 10.90 | 75.96 ± 12.80 | 0.577 |
| Fasting glucose (mmol/L) | 4.72 ± 0.35 | 5.00 ± 1.75 | 0.004 |
| HDL-cholesterol (mmol/L) | 1.31 ± 0.19 | 0.93 ± 0.28 | < 0.001 |
| LDL-cholesterol (mmol/L) | 1.67 ± 0.34 | 2.33 ± 0.88 | < 0.001 |
| Total Cholesterol (mmol/L) | 4.16 ± 0.51 | 3.71 ± 0.98 | 0.001 |
| Triglyceride (mmol/L) | 0.95 ± 0.24 | 1.39 ± 0.86 | < 0.001 |
| Serum creatinine (umol/L) | 91.11 ± 6.58 | 113.79 ± 32.89 | < 0.001 |
| Cystatin c (mg/L) | 1.05 ± 0.23 | 1.38 ± 0.42 | < 0.001 |
| NT-proBNP (ng/L) | 3.81 ± 2.55 | 9878.69 ± 9236.14 | < 0.001 |
| LVEF (%) | 59.25 ± 2.35 | 28.67 ± 6.18 | < 0.001 |
| CTRP3 (ng/mL) | 236.40 ± 62.86 | 173.30 ± 49.81 | < 0.001 |
| CTRP9 (ng/mL) | 180.70 ± 51.05 | 124.60 ± 37.58 | < 0.001 |
Data are expressed as mean ± SD or frequency (%)
P-values were calculated by an independent-samples t-test or chi-square test
BMI Body mass index, HDL High-density lipoprotein, LDL Low-density lipoprotein, NT-proBNP N-terminal pro-brain natriuretic peptide, LVEF Left ventricular ejection fraction, CTRP3 C1q/TNF-related protein 3, CTRP9 C1q/TNF-related protein 9
aThese data were acquired by inquiry of medical history